Making sense of cell fate
The timing and dosage of DNA-damaging drugs determine whether cancer cells die or enter senescence, according to a study from the MIT Koch Institute lab of Michael Yaffe. The work suggests clinical implications for combining chemotherapy with MEK inhibitors.